PureTech’s Seaport Therapeutics Doses First Patient in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder PureTech Health plc (LSE: PRTC) announced that its Founded Entity, Seaport Therapeutics (Nasdaq: SPTX), has dosed the first patient in a Phase 2a clinical…
PearlDX Publishes Clinical Evidence Supporting FDA-Cleared MycoMEIA Urine Test for Invasive Aspergillosis Pearl Diagnostics, also known as PearlDX, has announced the publication of new clinical studies supporting the U.S. Food and Drug Administration (FDA) 510(k) clearance of its MycoMEIA® Aspergillus…
Epicrispr Reports Six-Month Clinical Data for EPI-321 Gene Therapy in FSHD Epicrispr Biotechnologies, a clinical-stage biotechnology company developing epigenetic therapies, has announced updated six-month clinical data from the ongoing first-in-human Phase 1/2 study of EPI-321 in adults with facioscapulohumeral muscular…
Alliance Foundation Trials and Natera Launch Phase III NAVIGATE Trial to Evaluate MRD-Guided Breast Cancer Treatment Alliance Foundation Trials, LLC (AFT), a national organization focused on advancing innovative and practice-changing cancer clinical trials, and Natera, Inc. (NASDAQ: NTRA), a company…
Roquette to Showcase Pharmaceutical Excipients and Drug Delivery Solutions at CPHI Milan 2026 Roquette, a global provider of pharmaceutical excipients, drug delivery technologies and biopharmaceutical solutions, will showcase its broad portfolio and technical expertise at CPHI Milan 2026 in Italy.…
GeneDx to Launch Easy Order at 2026 AAP Conference to Simplify Genomic Testing for Pediatricians GeneDx, a company focused on rare disease diagnosis and improving health through genomic data, will introduce Easy Order, a new streamlined genomic testing experience designed…
ILiAD Biotechnologies Publishes Phase 2b SUPER Trial Results for Intranasal Pertussis Vaccine Candidate BPZE1 in The Lancet Infectious Diseases ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical-stage biotechnology company focused on preventing and treating diseases caused by Bordetella pertussis, has announced…
Verastem Oncology Presents New Data Supporting Avutometinib Plus Defactinib Across Molecular Subgroups in Recurrent LGSOC Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing new medicines for patients with cancers driven by the RAS/MAPK pathway, has announced new clinical…
AngioDynamics Supports Jacobi Hospital Study Investigating CT Pulmonary Angiography Radiomics in Pulmonary Embolism AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring blood flow within the vascular system, expanding cancer treatment options and improving patient quality of life,…
Inquis Medical Launches Latest AVENTUS Catheter in U.S. for Targeted Pulmonary Embolism Thrombectomy Inquis Medical, a medical device company developing technologies for the treatment of venous thromboembolic disease, has announced the U.S. commercial launch of its latest AVENTUS™ Catheter, expanding…
Blue Matter Launches Behavioral Science Center of Excellence to Decode Healthcare Decision-Making Blue Matter has announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the company’s Blue Matter Insights primary market research team…
TriLink BioTechnologies Expands CleanCap® Intellectual Property Protection With New China Patent TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, announced that it has received a new patent from the…